NCT03851588View on ClinicalTrials.gov

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

January 20, 2022

Study Completion Date

June 28, 2022

Conditions
HIV InfectionsTuberculosis
Interventions
OTHER

Placebo

Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.

DRUG

Dolutegravir 50 mg

Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.

Trial Locations (1)

8001

Khayelitsha Site B/Ubuntu Clinic, Cape Town

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

Medecins Sans Frontieres, Netherlands

OTHER

lead

University of Cape Town

OTHER

NCT03851588 - Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis | Biotech Hunter | Biotech Hunter